Daiichi Sankyo Company, Limited (DSKYF)

OTCMKTS · Delayed Price · Currency is USD
28.20
+0.50 (1.81%)
Dec 11, 2024, 4:00 PM EST
2.51%
Market Cap 52.83B
Revenue (ttm) 12.27B
Net Income (ttm) 1.75B
Shares Out n/a
EPS (ttm) 0.91
PE Ratio 30.23
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,700
Open 27.56
Previous Close 27.70
Day's Range 27.40 - 30.70
52-Week Range 25.95 - 44.64
Beta 0.28
Analysts n/a
Price Target n/a
Earnings Date Jan 31, 2025

About Daiichi Sankyo Company

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhi... [Read more]

Sector Healthcare
Founded 1899
Employees 18,726
Stock Exchange OTCMKTS
Ticker Symbol DSKYF
Full Company Profile

Financial Performance

In 2023, Daiichi Sankyo Company's revenue was 1.60 trillion, an increase of 25.28% compared to the previous year's 1.28 trillion. Earnings were 200.73 billion, an increase of 83.84%.

Financial numbers in JPY Financial Statements

News

England Pricing Talks Fail on Astra, Daiichi Breast Cancer Drug

AstraZeneca Plc and Daiichi Sankyo Co Ltd have once again failed to reach an agreement with England’s drug pricing regulator on the cost of a breast cancer medicine.

25 days ago - BNN Bloomberg

Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS

BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will highlight new clinical research and real-world data from seven abstracts for TURALIO® (pexidartinib) at the Connective Tissue Onco...

4 weeks ago - Business Wire

ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product

Daiichi Sankyo (TSE:4568) and AstraZeneca (NASDAQ: AZN) have been awarded The Galien Foundation 2024 Prix Galien USA Award for Best Biotechnology Product for ENHERTU ® (fam-trastuzumab deruxtecan-nxk...

5 weeks ago - Benzinga

Daiichi Sankyo Company, Limited (DSKYF) Q2 2025 Earnings Call Transcript

Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q2 2025 Earnings Conference Call October 31, 2024 2:30 AM ETCompany ParticipantsHiroyuki Okuzawa -...

6 weeks ago - Seeking Alpha

Daiichi Sankyo COO: Partnerships with Merck & AstraZeneca going very well

Daiichi Sankyo's chief operating officer, Hiroyuki Okuzawa speaks about the company's drug pipeline and alliances with global pharmaceutical firms.

6 weeks ago - CNBC

Daiichi Sankyo Eyes Newer Cancer Drugs to Stave off Rivals

Drugmaker Daiichi Sankyo is working to boost production of its newer-generation cancer therapies that target diseased cells, across Japan, Europe and the US.

2 months ago - BNN Bloomberg

Daiichi Sankyo and AstraZeneca's Enhertu Receives Priority Review from FDA for HER2 Low Breast ...

Daiichi Sankyo and AstraZeneca's Enhertu Receives Priority Review from FDA for HER2 Low Breast Cancer

2 months ago - GuruFocus

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy

Based on DESTINY-Breast06 Phase III trial which demonstrated a statistically significant and clinically meaningful progression-free survival benefit for ENHERTU If approved, AstraZeneca and Daiichi Sa...

2 months ago - Benzinga

AstraZeneca antibody drug candidate fails to meet overall survival goal in breast cancer

AstraZeneca and Daiichi Sankyo face setback as breast cancer drug fails to show significant overall survival benefit in final analysis. Read more here.

2 months ago - Seeking Alpha

Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial

Survival results for Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan in TROPION-Breast01 did not achieve statistical significance versus chemotherapy Trial previously met the dual primary endp...

2 months ago - Benzinga

Daiichi Sankyo: Showing No Signs Of Slowing Down ADC Dominance

Daiichi Sankyo's (DSNKY) ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

3 months ago - Seeking Alpha

Merck, Daiichi post late-stage trial win for novel lung cancer therapy

Merck (MRK) and Daiichi Sankyo's (DSNKY) lung cancer drug, patritumab deruxtecan hits the primary endpoint in a Phase 3 trial as a second-line therapy. Read more here.

3 months ago - Seeking Alpha

Daiichi Sankyo and Merck's cancer drug meets main goal in late-stage trial

Daiichi Sankyo and Merck said on Tuesday that their drug met the main goal in a late-stage study in patients with lung cancer.

3 months ago - Reuters

ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases

Daiichi Sankyo and AstraZeneca's ENHERTU achieved a 61.6% progression-free survival rate at one year in patients with active or stable brain metastases in DESTINY-Breast12 Largest prospective trial of...

3 months ago - Benzinga

ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases.

3 months ago - Business Wire

AstraZeneca Shares Set For Worst Week in 14 Months on Sell Calls

AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the British drugmaker’s experimental lung cancer medicine with partner Daiichi Sa...

3 months ago - BNN Bloomberg

Daiichi Sankyo Plunges on Mixed Trial Result of Lung Cancer Drug

Daiichi Sankyo Co. shares drop as much as 10.4% on Tuesday, the most since Aug. 5, after its lung cancer drug with AstraZeneca showed mixed results in a phase 3 trial.

3 months ago - BNN Bloomberg

Daiichi Sankyo Unveils New Research Across Industry-Leading ADC Portfolio in Multiple Cancers at WCLC and ESMO

BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Unveils New Research Across Industry-Leading ADC Portfolio in Multiple Cancers at WCLC and ESMO.

3 months ago - Business Wire

Daiichi Sankyo Shines a Light on Inequalities and Unmet Needs in Care as Part of Its Commitment to People With Cardiovascular Disease

MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care, by shining...

3 months ago - Business Wire

ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer

Daiichi Sankyo and AstraZeneca's ENHERTU has now been granted eight Breakthrough Therapy Designations with latest based on DESTINY-Breast06 phase 3 trial results Eleventh Breakthrough Therapy Designat...

4 months ago - Benzinga

Daiichi Sankyo Company, Limited (DSKYF) Q1 2024 Earnings Call Transcript

Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q1 2024 Earnings Conference Call July 31, 2024 5:00 AM ET Company Participants Toshinori Agatsuma - Head of R&D Division Koji Ogawa - Head of Global Corpo...

4 months ago - Seeking Alpha

Daiichi Sankyo Opens New Affiliate for Oncology in Greece

ATHENS, Greece--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today announced that it has opened a new affiliate for its oncology business in Athens, Greece. The establishment highlights the company's s...

5 months ago - Business Wire

Arbitration Dispute Between Daiichi Sankyo and Seagen Ends

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--A dispute between Daiichi Sankyo Co., Ltd. (TSE: 4568) and Seagen Inc. is now concluded and Seagen has paid Daiichi Sankyo approximately U.S. $47 million ...

6 months ago - Business Wire

Daiichi Sankyo Is Riding The ADC Revolution To Billions In Future Revenue

Daiichi Sankyo is poised to play its part in revolutionizing cancer treatments with its portfolio of antibody-drug conjugates, that target $15 billion-plus annual revenue opportunities. Enhertu, the p...

6 months ago - Seeking Alpha